PAXVAX, INC.

Basic Information

3985A SORRENTO VALLEY BLVD
SAN DIEGO, CA, 92121

http://www.paxvax.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 806518598
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 188


  1. Modernized Production of Enteric Coated Live, Oral Adenovirus Vaccine

    Amount: $1,000,000.00

    Adenoviruses are a frequent cause of epidemic acute respiratory disease (ARD) in military recruit training centers and pose a significant threat to military readiness, especially during times of large ...

    SBIR Phase II 2015 Department of Defense Defense Health Program
  2. HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP

    Amount: $801,463.00

    DESCRIPTION provided by applicant Development of a HIV vaccine to prevent or reduce the rate of infection remains a high priority The lessons from numerous failed and the recent modestly succe ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Modernized Production of Enteric Coated Live, Oral Adenovirus Vaccine

    Amount: $99,947.00

    Adenoviruses are a frequent cause of epidemic acute respiratory disease (ARD) in military recruit training centers and pose a significant threat to military readiness, especially during times of large ...

    SBIR Phase I 2014 Department of Defense Army
  4. Oral, replicating Ad4-HIV vaccine development and evaluation in NHP challenge model

    Amount: $2,971,235.00

    DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed an ...

    SBIR Phase II 2012 Department of Health and Human Services
  5. Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2

    Amount: $548,822.00

    DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed an ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Use of Spray-Drying as a Manufacturing Process for Oral Adenovirus Vaccine

    Amount: $298,464.00

    DESCRIPTION (provided by applicant): The 2009 H1N1 pandemic illustrates a critical weakness in our ability to respond to a pandemic threat. The ability to ramp up production of vaccine doses within th ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Ad4 vectored HIV-Env vaccines with improved immunogenicity

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed an ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government